A detailed history of Vanguard Group Inc transactions in Chroma Dex Corp. stock. As of the latest transaction made, Vanguard Group Inc holds 3,430,356 shares of CDXC stock, worth $18.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,430,356
Previous 3,386,425 1.3%
Holding current value
$18.8 Million
Previous $9.24 Million 35.44%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.51 - $3.8 $110,266 - $166,937
43,931 Added 1.3%
3,430,356 $12.5 Million
Q2 2024

Aug 13, 2024

BUY
$2.44 - $4.32 $825,466 - $1.46 Million
338,306 Added 11.1%
3,386,425 $9.24 Million
Q4 2023

Feb 14, 2024

BUY
$1.28 - $1.6 $5,730 - $7,163
4,477 Added 0.15%
3,048,119 $4.36 Million
Q2 2023

Aug 14, 2023

SELL
$1.31 - $1.79 $110,532 - $151,033
-84,376 Reduced 2.7%
3,043,642 $4.78 Million
Q1 2023

May 15, 2023

BUY
$1.48 - $2.19 $767,858 - $1.14 Million
518,823 Added 19.88%
3,128,018 $4.79 Million
Q4 2022

Feb 10, 2023

BUY
$1.25 - $1.94 $472,372 - $733,122
377,898 Added 16.94%
2,609,195 $4.38 Million
Q3 2022

Nov 14, 2022

BUY
$1.19 - $2.06 $58,135 - $100,637
48,853 Added 2.24%
2,231,297 $2.74 Million
Q2 2022

Aug 12, 2022

SELL
$1.59 - $2.7 $952,398 - $1.62 Million
-598,993 Reduced 21.54%
2,182,444 $3.65 Million
Q1 2022

May 13, 2022

BUY
$2.02 - $3.92 $485,636 - $942,422
240,414 Added 9.46%
2,781,437 $6.84 Million
Q4 2021

Feb 14, 2022

SELL
$3.74 - $6.7 $338,657 - $606,685
-90,550 Reduced 3.44%
2,541,023 $9.5 Million
Q3 2021

Nov 12, 2021

BUY
$6.05 - $10.41 $138,762 - $238,763
22,936 Added 0.88%
2,631,573 $16.5 Million
Q2 2021

Aug 13, 2021

BUY
$6.66 - $10.92 $17.4 Million - $28.5 Million
2,608,637 New
2,608,637 $25.7 Million

Others Institutions Holding CDXC

About ChromaDex Corp.


  • Ticker CDXC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,350,896
  • Market Cap $375M
  • Description
  • ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingre...
More about CDXC
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.